SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Speculating in Takeover Targets -- Ignore unavailable to you. Want to Upgrade?


To: richardred who wrote (2342)6/11/2018 1:27:44 PM
From: richardred  Read Replies (1) | Respond to of 7276
 
Stryker now wanting the whole company?

Boston Scientific shares rise on report that Stryker has made a takeover approach for company


    Medical device manufacturer Stryker approached rival Boston Scientific with a takeover bid, The Wall Street Journal reported Monday.
  • Shares of Boston Scientific rose nearly 10 percent after resuming trading.


cnbc.com

Message #2342 from richardred at 8/25/2010 12:54:20 PM

Stryker had 4 billion in cash now I know what there looking at.

UPDATE 1-Stryker to buy Gaymar for $150 million


* Stryker sees acquisition boosting earnings after 2011

* Gaymar now owned by two private equity firms

CHICAGO Aug 25 (Reuters) - Stryker Corp (SYK.N), a maker of orthopedic devices, hospital beds and surgical equipment, said it will acquire Gaymar Industries, which manufactures therapeutic mattresses and temperature-management products, for $150 million in cash.

The acquisition, expected to close by Oct. 1, is expected to be neutral to earnings in 2010 and 2011 and boost profits thereafter, Stryker said.

Gaymar, which had revenue of $77 million in 2009, has been owned by private equity firms Nautic Partners and Norwest Equity Partners since 2003.

Gaymar and Stryker, whose boards have approved the deal, have had a relationship under which Stryker has sold some Gaymar products.

"The acquisition of Gaymar Industries is consistent with our strategic goal of expanding our existing product offering and extensive sales force presence via innovative and value-added products," Chief Executive Stephen MacMillan said in a prepared statement.

Stryker is in advanced talks to buy Boston Scientific Corp's (BSX.N) neuromodulation business for about $1.5 billion, according to Bloomberg. (Reporting by Debra Sherman; editing by John Wallace)
reuters.com